

PRO 542



Drug Class: Entry and Fusion Inhibitors

PRO 542, also known as CD4-IgG2, is a type of medicine called an entry inhibitor. Entry inhibitors work by binding to and preventing HIV from infecting human CD4 cells, also called T cells.

HIV/AIDS-Related Uses

PRO 542 is an investigational medicine that is not yet approved by the FDA for use outside of clinical trials. It is being studied for the treatment of HIV infection. This medicine does not cure or prevent HIV infection or AIDS and does not reduce the risk of passing the virus to other people.

Dosage Form/Administration

PRO 542 comes in a liquid form and must be injected into a vein.

Contraindications

Individuals should tell a doctor about any medical problems before taking this medicine.

Possible Side Effects

Along with its desired effects, PRO 542 may cause some unwanted effects. These effects are not yet known. PRO 542 has been studied in small trials of HIV infected patients and no serious side effects have been reported.

Drug and Food Interactions

A doctor should be notified of any other medications being taken, including prescription, nonprescription (over-the-counter), or herbal medications.

Clinical Trials

For information on clinical trials that involve PRO 542, visit the ClinicalTrials.gov web site at <http://www.clinicaltrials.gov>. In the Search box, enter: PRO 542 AND HIV Infections.

Manufacturer Information

PRO 542
Progenics Pharmaceuticals, Inc.
777 Old Saw Mill Road
Tarrytown, NY 10591

For More Information

Contact your doctor or an AIDSinfo Health Information Specialist:

- Via Phone: 1-800-448-0440 Monday - Friday, 12:00 p.m. (Noon) - 5:00 p.m. ET
- Via Live Help: http://aidsinfo.nih.gov/live_help Monday - Friday, 12:00 p.m. (Noon) - 4:00 p.m. ET